Tunlametinib + AG + Cetuximab as First-Line Therapy for Advanced Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, single-arm clinical trial evaluating the safety and efficacy of tunlametinib in combination with gemcitabine/albumin-bound paclitaxel and an EGFR monoclonal antibody as first-line therapy in treatment-naive subjects with advanced pancreatic cancer.
Phase:
PHASE4
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital